Search Videos and More
News
Dana-Farber Investigators Pinpoint Keys to Cell Therapy Response for Leukemia
Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, will successfully move the patient into remission.
News
Dana-Farber Research News 01.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from December 1 through December 15.
News
Dana-Farber and Gustave Roussy Announce 2025 Transatlantic Exchange Scientific Program to Focus on Radioligand Therapy
Dana-Farber Cancer Institute and Gustave Roussy (Grand Paris, Villejuif, France) have announced that the Fourth Transatlantic Exchange in Oncology Conference topic will be “Radiopharmaceutical Therapy Meets Oncology.”
Video
Katie Maurer, MD, PhD discusses HSCT treatment
Katie Maurer, MD, PhD, from Dana-Farber Cancer Institute, shared #ASH24 findings suggesting that diverse bone marrow cell composition may predict treatment response in the content of AML patients undergoing HSCT.
Video
Shai Shimony, MD, MPH reviews Phase 3 acute myeloid leukemia trial
Findings from a Phase 3 acute myeloid leukemia trial presented at #ASH24 show CPX-351 improves survival for AML-MR patients. Lead authors Shai Shimony, MD, MPH, and H. Moses Murdoch, MD, of Dana-Farber Cancer Institute, explain more in this video.
Video
Colleen Kelly, MD discusses findings on RISE
At #ASH24, researcher, Colleen Kelly MD, presented findings on RISE, a Dana-Farber led program aiding low-income families of kids with cancer. Results show promise.
Video
Jacqueline Garcia, MD on oral maintenance therapy in AML/MDS patients
Jacqueline Garcia, MD, of Dana-Farber Cancer Institute presented at #ASH24 data suggesting oral maintenance therapy with venetoclax and decitabine/cedazuridine after HCT is safe, feasible, and may reduce relapse rates in high-risk AML/MDS patients.
Video
Matthew Davids, MD, MMSc discusses time-limited AVO triplet therapy
In a new study published in the Journal of Clinical Oncology and presented at #ASH24, Matthew Davids, MD, MMSC, of Dana-Farber Cancer Institute, shared promising findings: a time-limited AVO triplet therapy offers durable remission for high-risk CLL patients.
Video
Jennifer Brown, MD, PhD reviews Phase 2 Amplify trial
Dana-Farber Cancer Institute's Jennifer Brown, MD, PhD, shared results at #ASH24 from the Phase 3 AMPLIFY trial: novel oral regimens show promise for CLL with durable, deep responses.
Video
Ann Lacasce, MD, MMSc discusses treatment in early stage high-risk cHL patients
Ann Lacasce MD, MMSc, of Dana-Farber Cancer Institute presented findings at #ASH24 suggesting treatment with brentuximab vedotin and nivolumab can reduce toxicities and may decrease the need for radiation in early stage high-risk cHL patients.
Video
Daniel DeAngelo, MD, PhD on a novel systemic mastocytosis (SM) drug
Daniel DeAngelo, MD, PhD, of Dana-Farber Cancer Institute, presented findings at #ASH24 on two abstracts regarding a novel systemic mastocytosis (SM) drug with high response rates & a tool that identifies SM subtypes with 90% accuracy.
News
Study Finds Care After Donor Stem Cell Transplant Can Be Safely Shared Between Transplant Centers and Local Oncologists
Patients undergoing a donor stem-cell transplant for leukemia or other blood-related cancer require months of specialized follow-up care, traditionally delivered at the center where they received their transplant – often a serious challenge for those who live far away.